Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cork

Showing results (171-180 of 224) with videos related to

Pageof 23
Sort By:
Human Molecular Genetics|January 10, 2006
Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype contextHongmin Chen, Leon M Wilkins, Nazneen Aziz, et al.
The British Journal of Dermatology|January 29, 2000
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapyJ I Harper, I Ahmed, G Barclay, et al.
Paediatric Drugs|August 31, 2021
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical TrialAmy S Paller, Andreas Wollenberg, Elaine Siegfried, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 23, 2006
Trigger for group A streptococcal M1T1 invasive diseaseJason N Cole, Jason D McArthur, Fiona C McKay, et al.
The Journal of Dermatological Treatment|June 11, 2019
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2Michael J Cork, Laurent Eckert, Eric L Simpson, et al.
The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.
Dermatology and Therapy|June 16, 2017
Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic MoisturizerMark Jean-Ann Koh, Yoke Chin Giam, Hui Min Liew, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Trials|July 23, 2017
Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trialJoanne R Chalmers, Rachel H Haines, Eleanor J Mitchell, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
Pageof 23

Showing results (171-180 of 224) with videos related to

Sort By:
Pageof 23
Human Molecular Genetics|January 10, 2006
Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype contextHongmin Chen, Leon M Wilkins, Nazneen Aziz, et al.
The British Journal of Dermatology|January 29, 2000
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapyJ I Harper, I Ahmed, G Barclay, et al.
Paediatric Drugs|August 31, 2021
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical TrialAmy S Paller, Andreas Wollenberg, Elaine Siegfried, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 23, 2006
Trigger for group A streptococcal M1T1 invasive diseaseJason N Cole, Jason D McArthur, Fiona C McKay, et al.
The Journal of Dermatological Treatment|June 11, 2019
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2Michael J Cork, Laurent Eckert, Eric L Simpson, et al.
The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.
Dermatology and Therapy|June 16, 2017
Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic MoisturizerMark Jean-Ann Koh, Yoke Chin Giam, Hui Min Liew, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 7, 2020
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacyA S Paller, E C Siegfried, E L Simpson, et al.
Trials|July 23, 2017
Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trialJoanne R Chalmers, Rachel H Haines, Eleanor J Mitchell, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
Pageof 23